Clinical importance of influence of hormone replacement therapy on risk of colorectal carcinoma
Authors:
T. Fait
Authors‘ workplace:
Porodnicko-gynekologická klinika 1. LF UK a VFN Praha
Published in:
Prakt Gyn 2005; 9(3): 22-25
Overview
Objective:
To give summary studies´ results on influence of hormone replacement therapy on risk of colorectal carcinoma.
Methods:
Literary review.
Results:
The position of hormone replacement therapy in therapy of acute climacteric syndrome, prevention and therapy of urogenital atrophy is unchanged by results of recent studies. Hormone replacement therapy still stands in important position in prevention of postmenopausal osteoporosis after calcium and vitamin D supplementation. Prevention of ischaemic heart disease is abandoned. Other indications connected with long term therapy are in contradiction with risks of hormone therapy.
Benefit of hormone therapy in relative risk of colorectal carcinoma is proportional to length of it. Protection against colorectal carcinoma and colon adenoma is not taken for indication of hormone therapy. It could be regarded as positive side effect of individual useful long term hormone therapy. Personal history of colorectal carcinoma is not contraindication for hormone therapy.
Key words:
colorectal carcinoma, hormone replacement therapy
Sources
1. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy. Lancet 1997; 350: 1047-1059.
2. Fait T, Vokrouhlická J, Vrablík M, Jeníček J. Současné postavení hormonální substituční terapie. Čas Lék Čes 2004; 143: 447-52.
3. Fernandez E, Bosetti C, La Vecchia C et al. Sex differences in colorectal cancer mortality in Europe 1955-1996. Eur J Cancer Prev 2000; 9(2): 99-104.
4. Wei EK, Ciovannucci E, Wu K et al. Comparison of risk factors for colon and rectal cancor. Int J Cancer 2004; 108(3): 433-42.
5. Potter JD. Hormones and colon cancor. J Natl Cancer Inst 1995; 87: 1039-40.
6. Slattery ML, Samowitz WS, Holden JA. Estrogen and progesterone receptors in colon tumors. Am J Clin pathol 2000; 113: 364-8.
7. Qui Y, Langman MJ, Eggo MC. Targets of 17beta-oestradiol-induced apoptosis in colon cancer cells: a mechanism for the protective effects of hormone replacement therapy? J Endocrinol 2004; 181(2): 327-37.
8. Curtin K, Bigler J, Slattery ML et al. MTHFR C677T and A1298C polymorphisms: diet, estrogen and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2004; 13(2): 285-92.
9. Calle EE, Miracle-McMahill H, Thun MJ et al. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Nat Canc Instit 1995; 87(7): 517-23.
10. Chute GC, Willett WC, Colditz GA et al. A prospective study of reproductive history nad exogenous estrogens on the risk of colorectal cancer in women. Epidemiology 1991; 2(3): 201-7.
11. Jacobs EJ, White E, Weiss NS. Exogenous hormones, reproductive history and colon cancor. Cancer Causes and Control 1994; 5: 359-66.
12. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancor. J National Cancer Institute 1995; 87(14): 1067-71.
13. Wu-Wiliams AH, Lee M, Whittemore AS et al. Reproductive factors and colorectal cancer risk among Chinese females. Cancer Res 1991; 51: 2307-11.
14. Davis FG, Furner SE, Persky V et al. The influence of parity and exogenous female hormones on risk of colorectal cancer. Int J Cancer 1989; 43: 587-90.
15. Risch HA, Howe GR. Menopausal hormone use and colorectal cancer in Saskatchewan. Cancer Epidemiol Biomarkers Prev 1995; 4(1): 21-8.
16. Nanda K, Bastian LA, Hasselblad V et al. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis, Obstet Gynecol 1999, 93: 880-8.
17. Fernandez E, La Vecchia C, Braga C. Hormoner replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 1998; 7(4): 329-33.
18. Paganini-Hill A. Estrogen replacement therapy and colorectal cancer risk in elderly women. Dis Colon Rectum 1999; 42(10): 1300-5.
19. Mendelson MT, Miglioretti D, Newcomb PA et al. Hormone replacement therapy in relation to survival in women diagnosed with colon cancer. Cancer Causes and Control 2003; 14: 979-84.
20. Slattery ML, Ballard-Barbash R, Edwards S et al. Body mass index and colon cancer. Cancer Causes Control 2003; 14(1): 75-84.
21. Writing Group for the Women´s Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women.Principal Results From the Women’s Health Initiative Randomized Controlled Trial. JAMA 2002; 288(3): 321-33.
22. The Women’s Health Initiative Steering Committee: Effects of CEE in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701-12.
23. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350(10): 991-1004.
24. Csizmadi I, Collet JP, Benedett A et al. The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women. BJC 2004; 90(1): 76-81.
25. Potter JD, Bostick RM, Grandits GA et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of large bowel. Cancer Epidemiol Biomarkers Prev 1996; 5: 513-8.
26. Jacobson JS, Neugut AI, Garbowski GC et al. Reproductive risk factors for colorectal adenomatous polyps. Cancer Causes Control 1995; 6: 513-8.
27. Grodstein F, Martinez ME, Giovannucci EL et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998; 28: 705-12.
28. Peipins LA, Newman B, Snadler RS. Reproductive history, use of exogenous hormones and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1997; 6: 671-5.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Practical Gynecology
2005 Issue 3
Most read in this issue
- Role of procalcitonin in diagnostics of neonatal infection
- The issue of malignant tumours of vulva
- Breast feeding still non replaceable I.
- Inherited thrombophilias and cytogenetic findings in patients with repeated fetal loss